This brand name is authorized in Israel, Japan
The drug DIFOLTA contains one active pharmaceutical ingredient (API):
|
1
Pralatrexate
UNII A8Q8I19Q20 - PRALATREXATE
|
|
Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer. Pralatrexate is used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01BA05 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BA Folic acid analogues | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 7090 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 4229404A1027 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
